Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Dar Global

    MCap

    USD1,486m

    Last close

    USD8.25

    ▲ −0.25 (−2.94%)

    Theon International

    MCap

    EUR875m

    Last close

    EUR12.50

    ▲ 1.44 (13.02%)

    Metals One

    MCap

    GBP2m

    Last close

    GBP0.00

    ▲ 0.04 (8.89%)

  • Sectors

    Sectors

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Context Therapeutics: Edison Open House Healthcare 2022

Context Therapeutics: Edison Open House Healthcare 2022

Context Therapeutics — 4 videos in collection

More on this equity

Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with hormone-dependent cancer.

• Tell us about the types of cancer that affect predominantly women and Context Therapeutics’ distinctive approach in this area?
• Is it correct that you are currently unique in this large market?
• How did you identify this opportunity?
• Tell us about your development pipeline, including your lead asset ONA-XR?
• Please explain the term ‘bispecific monoclonal antibody’ and why is it relevant in this context?
• How does the recent acquisition fit in with your future plans and does it indicate other in-licensing opportunities in the near or medium term?
• What can you tell us about the plan to commercialise your asset pipeline?
• Which options are you considering for further fund-raising?
• Which milestones should investors focus on in the coming year?

< Previous
Next >

You may also be interested in these:

Healthcare

Context Therapeutics webinar: Claudin 6 x CD3 bispecific antibody data update

Healthcare

Context Therapeutics: Identification of CTIM-76, a CLDN6xCD3 bi-specific antibody

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free